Key result
High-dose bucindolol links to ~60% lower all-cause mortality vs no/low-dose in ADRB1 Arg389Arg genotype patients.
Why the study?
Does high-dose beta-blocker therapy reduce all-cause mortality compared to no/low-dose therapy in HFrEF patients stratified by ADRB1 Arg389Gly polymorphism genotypes?
Population
1,997 patients with heart failure with reduced ejection fraction from the BEST and HF-ACTION DNA substudies…
Comparison
High-dose beta-blockers vs No or low-dose beta-blockers
Design
Cohort
Authors
Loading...
High-dose beta-blockers were associated with lower mortality in ADRB1 Arg389Arg HFrEF; hypothesis-generating for genotype-guided titration pending prospective trials.
Does high-dose beta-blocker therapy reduce all-cause mortality compared to no/low-dose therapy in HFrEF patients stratified by ADRB1 Arg389Gly polymorphism genotypes?
High-dose beta-blocker therapy provides a significant mortality benefit over low-dose therapy specifically in HFrEF patients with the ADRB1 Arg389Arg genotype, supporting guideline recommendations to titrate beta-blockers to target doses.
Parikh et al. (2018) studied this question. High-dose bucindolol reduced all-cause mortality by 60% in ADRB1 Arg389Arg genotype patients compared to no/low-dose treatment, indicating increased efficacy at higher doses.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: